Want to see SE:PROGEN full AI Analyst Report?
PROGEN Stock Chart & Stats
kr0.75
-kr0.32(-6.69%)
At close: 4:00 PM EST
kr0.75
-kr0.32(-6.69%)
Day’s Range― - ―
52-Week Rangekr0.11 - kr0.87
Previous CloseN/A
Volume7.01K
Average Volume (3M)300.11K
Market Cap
kr95.89M
Enterprise Valuekr12.73M
Total Cash (Recent Filing)kr9.07M
Total Debt (Recent Filing)kr5.30M
Price to Earnings (P/E)―
Beta-0.72
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding532,703,900
10 Day Avg. Volume460,844
30 Day Avg. Volume300,114
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr1.23M
Bulls Say, Bears Say
Bulls Say
Focused Product OfferingA narrowly focused prognostic genomic test for prostate cancer is a durable business foundation: it targets a high-value clinical decision point, benefits from specialty adoption paths (urology/oncology), and can generate recurring per-test revenue as clinical guidelines and payer coverage evolve.
Balance Sheet CushionModerate leverage and positive equity give the company financial flexibility over months: the ~0.20 debt/equity ratio and material equity buffer reduce immediate solvency risk and improve capacity to raise capital or withstand operating losses while pursuing commercial scale.
Lean Operating FootprintA very small headcount implies a lean cost base and operational flexibility, which can extend runway and enable focused investment into commercialization or lab scale-up. For a diagnostics firm, low fixed overheads can help preserve cash while pursuing reimbursement and customer adoption.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow creates a structural funding need: ongoing cash burn forces reliance on external financing or dilution, constrains investment in commercialization, and limits the company’s ability to scale tests and labs without material capital infusions.
Negative Unit EconomicsA heavily negative gross margin indicates the per-test cost base exceeds revenue, a durable commercial problem. Unless pricing, reimbursement, or cost structure is materially improved, the business cannot scale profitably and will continue to require subsidization to grow volumes.
Declining RevenueRecent revenue decline reduces operating leverage and undermines growth trajectory: shrinking sales make it harder to dilute fixed costs, extend cash runway, and validate clinical adoption, increasing execution risk and the need for strategic fixes to regain momentum.
PROGEN FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was kr0.11 and its highest was kr0.87 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is kr95.89M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 31, 2026 which is in 40 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -kr0.151 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.151.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 532,703,900 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -kr0.151 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.8%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in SE:PROGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.